Category: Product Launch
News about product and service launches
New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell... Read more
New Sample Preparation Solution Simplifies Food Safety Testing
The Thermo Scientific QuEChERS portfolio delivers robust, sensitive quantitation in compliance with global regulatory requirements LANGERWEHE, Germany, Dec. 9, 2021 /PRNewswire/ — Food industry, government and contract testing laboratories performing food safety analysis can now benefit from a new portfolio that offers cost-effective, robust Solid-Phase Extraction (SPE) solutions to support food safety workflows and meet regulatory... Read more
PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance
New NGS workflow accelerates the detection of SARS-CoV-2 variants including Omicron WALTHAM, Mass.–(BUSINESS WIRE)–Dec. 8, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the research use only (RUO) launch of the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next... Read more
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares... Read more
Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instruments TIB Molbiol will continue to focus on the research and development... Read more
New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing
New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications CARLSBAD, Calif., Nov. 30, 2021 /PRNewswire/ — For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen... Read more
GE Healthcare Announces Three New Alliances to Help Improve Cancer Care
Collaborations with SOPHiA GENETICS, The University of Cambridge and Optellum are intended expand access to the latest and most advanced technologies for cancer care Chicago, Nov 30 2021 — GE Healthcare announced collaborations with SOPHiA GENETICS, The University of Cambridge and Optellum as part of its vision to advance care, make precision health more accessible,... Read more